header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

NEW COMPOSITE SCAFFOLD AND MESENCHYMAL STEM CELLS IN TREATMENT OF ARTICULAR CARTILAGE DEFECT



Abstract

Objective: Assorted treatment methods of articular cartilage injury are known. The using of allogenic MSCs (Mesenchymal stem cells) get from bone marrow blood brings combinated with new composite collagen/chi-tosan scaffold new possibilities in treatment of these defects. The aim of our study was to examine the therapeutic effect of this transplantation.

Methods: Experimental group A (20 miniatuture pigs), allogenic MSCs in composite scaffold were transplanted into a iatrogenic defect on articular cartilage of lateral condyle of left distal femur. Control group B (20 miniatuture pigs), only composite scaffold were transplanted into a iatrogenic defect on articular cartilage in the same place. The finally results in both groups were by histological examination (H-E, PAS, ELISA, FISH – MSCs was with labeled fluorochrome CM-DiI) determinated. For objective evaluation we used the histological - histochemical O’Driscoll score.

Results: In group A the ‘Driscoll score (quality of cartilage healing) was 16,3±2,2, in group B 10,0±1,56. Imunohistochemical examination the collagen II fibres detected in group A in 80%, FISH detected fluorochrome CM-DiI in 75% in new cartilage.

Conclusion: MSCs transplantation leads to much better resluts of healing compared with untreated defects in control group (only scaffold transplnatation). Supported by the Research Projects of MSMT (NPV II 2B06130).

Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Email: office@efort.org